TECHNOLOGY

Introducing our

A Novel Patented Technology to Separate Cancer
Cells from Blood

  • Circulating Tumour Cells (CTC) enrichment system
  • Label-free, viable and intact CTSs
  • Short turnaround with minimal hands-on
  • Compact and intuitive design
  • 30-Day Return Policy (terms and conditions apply)
Mission

Pioneering

Innovative Diagnostic Solutions

Applications

Transforming Healthcare

with Technology.

Inspiring Better Health

Listed on the Singapore Stock Exchange, Biolidics Limited focuses on developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.

To diversify our business model and build long term growth, the Group is also actively exploring technology-enabled lifestyle businesses, which would involve the ownership, operation and management of Multi-Channel Networks ("MCN") businesses, live streaming social e-commerce platforms and Esports-related businesses.

Technology

ClearCell® FX1 System

ClearCell® FX1 System

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

Value Propositions

Value Propositions

Fully automated and entirely label-free, Biolidics’ ClearCell® FX1 System, with the patented microfluidic biochip, CTChip® FR1, the ClearCell® FX1 System achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer.

Applications

Applications

The wholly intact and viable CTCs isolated using our ClearCell® FX1 System are collected in a liquid suspension and can be transferred to various formats, such as glass slides and microtiter plates, for easy integration with routine pathology laboratory workflows.

Locate Us
Contact Us